The regulatory greenlight allows Prelude to initiate testing for PRT12396 in patients with myeloproliferative neoplasms, a group of rare blood cancers. Management expects to dose the first patient by the second quarter of this year. Following the announcement, the company's stock rose 9.4% to $2.22 in morning trading, extending a rally that has seen the share price double over the last 12 months.

Strategic Pivot and Partnerships

CEO Kris Vaddi characterized the FDA’s Investigational New Drug clearance as a "pivotal first milestone" in the company’s broader strategic overhaul. This shift focuses resources on high-potential oncology targets, specifically the JAK2 and KAT6 pathways. The PRT12396 program is currently governed by an exclusive option agreement with Incyte, a partnership that could provide financial and operational support as the drug progresses through the clinic.

The market's positive reaction reflects growing investor confidence in Prelude’s pipeline after a year of substantial growth. While the company remains in the early stages of clinical development, the collaboration with Incyte adds a layer of validation to its therapeutic approach, according to the company's latest strategic outline. The trial will evaluate the safety and efficacy of the drug in a patient population with limited treatment options.